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Nonhematopoietic bone marrow mesen-
chymal stem cells (BM-MSCs) are of cen-
tral importance for bone marrow stroma
and the hematopoietic environment. How-
ever, the exact phenotype and anatomical
distribution of specified MSC populations
in the marrow are unknown. We character-
ized the phenotype of primary human
BM-MSCs and found that all assayable
colony-forming units-fibroblast (CFU-Fs)
were highly and exclusively enriched not
only in the lin/CD271/CD45/CD146
stem-cell fraction, but also in lin/CD271/
CD45/CD146/low cells. Both popula-
tions, regardless of CD146 expression,
shared a similar phenotype and geno-
type, gave rise to typical cultured stromal
cells, and formed bone and hematopoi-
etic stroma in vivo. Interestingly, CD146
was up-regulated in normoxia and down-
regulated in hypoxia. This was correlated
with in situ localization differences, with
CD146 coexpressing reticular cells lo-
cated in perivascular regions, whereas
bone-lining MSCs expressed CD271
alone. In both regions, CD34 hematopoi-
etic stem/progenitor cells were located in
close proximity to MSCs. These novel
findings show that the expression of
CD146 differentiates between perivascu-
lar versus endosteal localization of non-
hematopoietic BM-MSC populations,
which may be useful for the study of the
hematopoietic environment. (Blood. 2011;
117(19):5067-5077)
Introduction
Human bone marrow contains a rare population of nonhematopoi-
etic mesenchymal stem cells (BM-MSCs), which are multipotent
and can differentiate in vivo toward skeletal lineages such as
osteoblasts, adipocytes, and chondrocytes, as well as toward
fibroblastic stromal cells.1-3 In vitro, clonogenic cells—denoted as
colony-forming units, fibroblast (CFU-Fs)—can be assayed from
the bone marrow as plastic adherent cells giving rise to fibroblastic
colonies. These CFU-Fs are considered to reflect primary
BM-MSCs, and on further proliferation in culture, their descen-
dants make up the well-known and extensively studied cultured
mesenchymal stromal cells.4
Bone marrow CFU-Fs express surface markers such as STRO-
1,5 CD271 (nerve growth factor receptor [NGFR]),6,7 stage-specific
embryonic antigen-4 (SSEA-4),8 GD2 (disialoganglioside 2),9
CD49a (integrin -1),10 and CD146 (melanoma cell adhesion
molecule [MCAM]).3,11 To date, these different CFU-F markers
have not been used in combination, and it is therefore not known
whether they identify the same cells or whether different subtypes
of early nonhematopoietic stem and progenitor cells coexist in the
bone marrow.
Culture-expanded CD146 cells have been demonstrated to
reestablish the hematopoietic microenvironment (HME) in a xeno-
transplantation model, and the transplanted cells colocalized with
suggested HSC niches in the bone marrow.3 Therefore, BM-MSCs
are likely to be relevant for human HME and stem cell niche
anatomy and function. However, a precise phenotypic definition of
the human stem cell niche cellular components has thus far been
elusive, in contrast to the murine system, in which different niche
cell types have been recently described.12-15
We report herein that nonhematopoietic human BM-CFU-Fs are
highly and exclusively enriched in lin/CD271/CD45/CD146
cells and in lin/CD271/CD45/CD146/low cells. Whereas CD271
expression identifies all assayable BM-CFU-Fs, different expres-
sion patterns of CD146 are correlated with in situ localization
differences: subendothelial sinusoidal CFU-Fs display the primary
CD271/CD146 phenotype, whereas bone-lining CD271 CFU-Fs
are predominantly CD146/low. In both locations, CD34 hemato-
poietic stem/progenitor cells are located in close proximity, which
might enable for the first time the prospective investigation and




Sixty milliliters of bone marrow was aspirated from the iliac crest bone of
consenting healthy donors. This procedure was approved by the University
of Lund ethics committee. Bone marrow mononuclear cells (BM-MNCs)
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were isolated by density gradient centrifugation using LSM 1077 Lympho-
cyte Separation Medium (PAA Laboratories) either with or without prior
incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment
Cocktail (StemCell Technologies) for lineage depletion (CD3, CD14,
CD19, CD38, CD66b, and glycophorin A).
FACS
Lineage-depleted BM-MNCs were incubated in blocking buffer (Dulbecco
PBS [DPBS] without Ca2, Mg2, and 3.3 mg/mL of human normal
immunoglobulin [Gammanorm; Octapharm] and 1% FBS [Invitrogen]) to
prevent unspecific binding, followed by staining with monoclonal antibod-
ies against CD45, CD146, and CD271 (see supplemental Methods,
available on the Blood Web site; see the Supplemental Materials link at the
top of the online article). Sorting gates were set according to the
corresponding fluorescence-minus-one (FMO) controls. Cells were sorted
on a FACSAria I or a FACSDiva flow cytometer (both BD Biosciences).
Dead cells were excluded by 7-amino-actinomycin (7-AAD; Sigma)
staining, and doublets were excluded by gating on forward scatter-height
versus forward scatter-width and side scatter-height versus side scatter-width.
Generation of cultured mesenchymal stromal cells
Sorted BM-MNCs were cultured in standard MSC culture medium (NH
Expansion Medium [Miltenyi Biotec] plus 1% antibiotic-antimycotic
solution [Sigma-Aldrich]). Medium was changed weekly and cells were
passaged at 70% confluence after trypsinization (0.05% trypsin/EDTA;
Invitrogen). Trypsinized cells were replated at 500-1000 cells/cm2.
Mesenchymal stromal cells for intra-bone marrow transplantation or
subcutaneous transplantation with hydroxyapatite/tricalcium phosphate
(HA/TCP) carriers were initiated from sorted CD271/CD45/CD146/low
and CD271/CD45/CD146 BM-MNCs, respectively. Sorted cells were
initially plated at 20-50 cells/cm2, and adherent cells were culture expanded
as described in the beginning of this section. Green fluorescent protein
(GFP)–labeled cells for intra-bone marrow transplantation were produced
by transducing 0. passage cells (before the first passaging) with a lentiviral
vesicular stomatitis virus glycoprotein GFP vector, followed by sorting of
GFP cells 2 weeks after transduction and an additional 3 weeks of culture
until transplantation.
CFU-F assay
CFU-F frequencies of BM-MNC populations were determined as described
previously.16,17 Briefly, FACS-sorted cells were cultured at plating densities
of 1-50 cells/cm2 when assaying CD271/CD45/CD146/low and CD271/
CD45/CD146 sorted cells and at 5000 cells/cm2 for sorting viable and
CD45 cells. Colonies were counted after 14 days (1% crystal violet;
Sigma-Aldrich). Generally, assays were set up in duplicates or triplicates.
For single-cell CFU-F assays, cells were sorted into fibronectin-coated,
96-well plates and cultured in MSC medium. Single-cell–derived colonies
were counted after 3 weeks, harvested by trypsinization, and split for
continued culture for in vitro differentiation and FACS analysis, respectively.
Hematopoietic progenitor and LTC-IC assays
For long-term culture-initiating cell (LTC-IC) assays, CD271/CD45 popula-
tions were sorted from MACS-enriched primary CD271 BM-MNCs
(CD271 MicroBead kit; Miltenyi Biotec). Cells were resuspended in
IMDM plus 2% FBS (both Invitrogen) and seeded into methylcellulose
medium (HSC-CFU complete with Epo; Miltenyi Biotec). After 2 weeks of
culture, hematopoietic colonies were analyzed under a microscope accord-
ing to standard criteria.
The stroma-supporting capacities of cultures generated from sorted
CD271/CD45/CD146/low and CD271/CD45/CD146 cells were as-
sessed with standard LTC-IC assays. Briefly, 3  105 cells were plated in
collagen-coated, 35-mm culture dishes and irradiated the following day
(16 Gy). Forty-eight hours after irradiation, 3000 MACS-enriched human
cord blood CD34 cells were seeded and cultured in MyeloCult H5100
medium (StemCell Technologies) with 103mM hydrocortisone (Sigma-
Aldrich) with weekly half-medium changes. After 6 weeks, cells were
harvested by trypsinization and assayed for hematopoietic colony forma-
tion, as described in the beginning of this section.
Flow cytometry
Cultured cells were harvested (0.05% trypsin/EDTA) and washed, and
unspecific binding was blocked with human normal immunoglobulin. Cells
were stained for 45 minutes at 4°C with combinations of antibodies.
Samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Freshly isolated, RosetteSep-depleted BM-MNCs were stained with a
combination of antibodies, including CD271, CD146, and CD45. Analysis
was performed on an LSR II flow cytometer (BD Biosciences). For
antibodies and suppliers, see supplemental Methods. Dead cells were
excluded by 7-AAD staining. For all samples analyzed on the LSR II,
doublets were excluded. Intracellular staining for nestin was performed on
fixed and permeabilized cells (Cytofix/Cytoperm Kit; BD Biosciences)
using FITC-conjugated anti–human-nestin antibody and the corresponding
isotype control (both R&D Systems).
In vitro differentiation assays
Cultured BM mesenchymal stromal cells were differentiated toward the
adipogenic, osteoblastic, and chondrogenic lineage, as described previ-
ously.16,17 Briefly, cells were cultured for 14 days in AdipoDiff medium
(Miltenyi Biotec), and cells were stained with Oil Red O (Sigma-Aldrich).
For osteogenic differentiation, cells were cultured in osteogenesis induction
medium (standard MSC medium supplemented with 0.05mM ascorbic acid
[Wako Chemicals] and 0.1M dexamethasone and 10mM -glycerophos-
phate [both from Sigma-Aldrich]) for 21 days, and calcium depositions in
the cultures were detected with Alizarin Red (Sigma-Aldrich). Chondro-
genic differentiation was accomplished by culturing cell pellets (2.5  105
cells/pellet) for 28 days in chondrogenesis induction medium (DMEM
high-glucose medium supplemented with 0.1M dexamethasone, 1mM
sodium pyruvate, and 0.35mM L-proline [all from Sigma-Aldrich], 0.17mM
ascorbic acid [Wako Chemicals], 1% ITS plus (insulin transferrin selerium)
culture supplements [BD Biosciences], and 0.01 g/mL of TGF-3 [R&D
Systems]). Pellets were paraformaldehyde fixed and frozen in O.C.T.
Compound (Sakura). Cryosections were stained against aggrecan (see
supplemental Methods) and toluidine blue and Alcian blue (both Sigma-
Aldrich). For aggrecan stainings, nuclei were stained with 4,6-diamidino-
2-phenylindole (Invitrogen). Sections were analyzed with a fluorescence
microscope (BX51; Olympus) and a digital camera (DP70; Olympus) using
DP manager software version 1.1.1.71 (Olympus).
Single-cell multiplex PCR
For single-cell PCR, CD271/CD45/CD146/low and CD271/CD45/CD146
BM-MNCs were sorted into 96-well plates (Thermo Scientific) containing
4 L/well of lysis buffer (2.5mM dNTP [Takara Bio] plus 10% NP40, 0.1M
DTT, and 40 U/mL of RNase Out [all Invitrogen]). Plates were spun, frozen, and
stored at 80°C until analysis. Reverse transcription/first-strand synthesis was
performed at 37°C for 60 minutes after adding Moloney murine leukemia
virus–reverse transcriptase (200 U/L) and 5 first-strand buffer (both Invitro-
gen) and outer reverse primers to each well. The first round of PCR was
performed with 10 L of reverse transcriptase reaction, outer forward primers,
and Taq polymerase (Takara Bio) at 94°C for 1 minute, 60°C for 1 minute, and
72°C for 2 minutes for 34 cycles and then 72°C for 7 minutes. The second round
of PCR was performed for each gene with 1 L of first-round PCR product, the
inner primer pair, and Taq polymerase at 94°C for 30 seconds, 60°C for 1 minute,
and 72°C for 1 minute for 34 cycles and then 72°C for 7 minutes. PCR products
were loaded on 2% agarose E-gels with E-Gel Low-Range DNA Ladder (both
Invitrogen) and analyzed. Primer sequences are provided in supplemental
Methods.
In vivo transplantation
For orthotopic transplantations, 1  106 GFP mesenchymal stromal cells
generated from sorted CD271/CD45/CD146/low and CD271/CD45/
CD146 BM-MNCs were injected intrafemorally into irradiated (2 Gy)
6- to 8-week-old NOD–Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. After 8 weeks,
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mice were killed by cervical dislocation and femurs were removed and
fixed in paraformaldehyde. After decalcification, permeabilization, and
dehydration, specimens were embedded in paraffin for analysis.
For analysis of in vivo bone and stroma formation, cultured MSCs were
derived from sorted CD271/CD45/CD146/low and CD271/CD45/
CD146 cells. Cells were loaded overnight on HA/TCP ceramic powder,
and 4  105 cells were implanted subcutaneously into 8-week-old female
NOD/SCID mice (4 implants per culture). Implants were removed after
8 weeks, fixed, decalcified, and paraffin embedded. Sections were stained
with hematoxylin/eosin and analyzed as described previously.18 All animal
procedures were approved by the local ethical committees on animal
experiments.
Immunofluorescence staining of bone sections
Paraffin sections from human bone marrow and mouse femurs were
deparaffinized and rehydrated following standard protocols. Heat-induced
epitope retrieval was applied using citrate buffer, pH 6 (Target Retrieval
Solution; Dako) for 30 minutes at 98°C. Sections were blocked/
permeabilized with Dulbecco PBS and 0.3% Triton X-100 (Sigma-
Aldrich), 10% normal goat serum, 0.1% sodium azide, and 0.1% cold
fish-skin gelatin (Sigma-Aldrich), and stained for 1 hour at room tempera-
ture or overnight at 4°C with primary antibodies. After washing, secondary
staining was performed for 1 hour at room temperature (for antibodies, see
supplemental Methods). TO-PRO-3 (Invitrogen) was used as a nuclear
stain. Photographs were taken on a confocal microscope (DMRE; Leica)
equipped with green helium/neon, standard helium/neon, and argon lasers
using Confocal Software v2.61 (Leica).
Hypoxia experiments
Stromal cultures generated from unfractionated bone marrow were cultured
with the addition of 100M deferoxamine mesylate in a standard incubator
with daily medium changes. After 1 week, cells were analyzed by FACS for
the expression of CD146 and other surface markers.
Cultures generated from unfractionated bone marrow were cultured in a
hypoxic chamber set to 1% O2 in standard MSC medium with weekly
medium changes. After 2 weeks, cells were analyzed by FACS for the
expression of CD146 and other surface markers (see supplemental Methods).
Results
CFU-Fs are highly and exclusively enriched in CD271/CD45
BM-MNCs expressing either CD146/low or CD146
Human BM-MNCs were stained with antibodies against CD146,
CD271, and CD45 (Figure 1A-B). Without CD45 exclusion,
CD271/CD146 populations contained large numbers of hematopoi-
etic cells, (43%, 97%, and 88% of CD271/CD146, CD271/
CD146, and CD271/CD146 cells, respectively; n  9). As
shown in Figure 1C, we detected 0.02%	 0.005% CD271/CD45/
CD146, 0.01% 	 0.003% CD271/CD45/CD146, and
0.06% 	 0.02% CD271/CD45/CD146 cells within viable hu-
man BM-MNCs (data are mean	 SEM; n  9).
We next assessed the CFU-F frequency of the different CD271/
CD146 cell populations in lineage-depleted bone marrow (Figure
1D-G). CFU-Fs were highly and exclusively enriched in the
CD271/CD45/CD146/low and CD271/CD45/CD146 cells.
In contrast, colony growth was not observed in either CD45 or the
CD271 cell fractions regardless of CD146 expression (Figure 1F).
No CFU-Fs were lost by lineage depletion (supplemental Figure 1)
Mean CFU-F frequencies were 4.2	 1.6 CFU-Fs per 100 plated
CD271/CD45/CD146/low cells and 2.0 	 0.7 CFU-Fs per
100 CD271/CD45/CD146 cells compared with 0.005 	 0.001
CFU-Fs per 100 viable cells in lineage-depleted BM-MNCs
(Figure 1F).
The colony-forming potential of the 2 CFU-F–containing
populations was confirmed by single-cell assays. CFU-F frequen-
cies were 3.5 	 0.9 and 1.6 	 0.7 per 96-well plate for CD271/
CD45/CD146/low and CD271/CD45/CD146 cells, respec-
tively (n  8; Figure 1G). Single-cell sorting accuracy as estimated
by bead sorting was 100%.
Whereas CD146 expression on CD271 cells did not discrimi-
nate between colony-forming and non–colony-forming cells, CD45
expression did; the majority of CD271 cells coexpressed CD45,
and clear morphologic differences were observed between the
CD271/CD45 and CD271/CD45 cell populations (supplemen-
tal Figure 2B).
In addition to CFU-F potential, sorted bone marrow cell
populations were also tested for hematopoietic colony growth in
standard methylcellulose assays. Erythroid colonies were observed
at low frequencies when CD271/CD45 cells were plated, but
were absent in other sorted cell fractions (supplemental Figure 2).
Both CD271/CD45/CD146/low and CD271/CD45/CD146
BM-MNCs give rise to typical cultured mesenchymal
stromal cells
We generated mesenchymal stromal cell cultures from both
CD271/CD45/CD146/low and CD271/CD45/CD146 cells
derived from either bulk- or single-sorted cells. Both populations
grew in standard MSC medium as typical adherent, spindle-shaped,
fibroblastic-like cells (Figure 2A), and no significant differences in
colony size between CD146 cells (2.1 	 0.1 mm; n  46) and
CD146/low cells (1.9 	 0.08 mm; n  51) could be observed
(Figure 2B). In addition, cultured cells from both populations
exhibited similar differentiation potential in vitro toward the
osteoblastic (Alizarin Red staining; some clones were additionally
stained with von Kossa/ALP), adipogenic (Oil Red O staining), and
chondrogenic (aggrecan, toluidine blue, and Alcian blue staining)
lineages. This was observed for both single-cell–derived clonal
cultures (Figure 2C) and multiclonal cultures from bulk-sorted
cells. A sufficient number of cells to test for trilineage differentia-
tion were generated from 14 of 20 clones, 8 of which showed
differentiation into all 3 lineages (2 of 3 CD146 clones and 6 of
11 CD146/low clones). The remaining 6 clones showed either
2-lineage differentiation capacity (n  3) or only unilineage differ-
entiation capacity (n  3). Sufficient cells for testing bilineage
differentiation capacity (osteoblasts and adipocytes) could be
generated from 2 additional clones, 1 of which showed bilineage
capacity and the other unilineage capacity for osteoblastic differen-
tiation. Furthermore, 2 additional clones could be only tested for
osteoblastic differentiation and both of them were positive. In
general, bilineage or unilineage clones possessed osteoblastic
potential but lacked or lost adipogenic and/or chondrogenic
potential. Furthermore, stromal cell cultures generated from
CD271/CD45/CD146/low and CD271/CD45/CD146CFU-Fs
(single-cell as well as bulk) exhibited similar surface-marker
profiles when analyzed for expression of typical MSC marker
profiles (ie, cells were positive for CD105, CD90, CD73, and
HLA-class I, and negative for CD34, CD45, CD14, CD19, and
HLA-DR; Figure 2D and supplemental Figure 3). Moreover,
cultures derived from CD271/CD45/CD146/low and CD271/
CD45/CD146 cells showed no differences in stroma-supporting
capacity, as indicated by standard LTC-IC assays (21.0 	 3.0 vs
20.7 	 3.5 colonies per 1000 seeded CD34 cells; n  3).
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Primary CD271/CD146/low and CD271/CD146 CFU-Fs share
a similar phenotype
We compared the uncultured CD271/CD45/CD146/low and
CD271/CD45/CD146 CFU-F–containing populations based
on morphology, FACS profile, and gene expression. As shown in
Figure 3, freshly sorted cells before attachment were round and
displayed reticular extensions (Figure 3A-B left). After attach-
ment, cells displayed a large, flat, branched-out fibroblastic
morphology (Figure 3A-B right). In addition, cytospin prepa-
rations were prepared to study nuclear morphology and cyto-
plasm properties of freshly isolated cells in more detail (sup-
plemental Figure 4A-C). CD271/CD45/CD146/low and
CD271/CD45/CD146 cells were characterized by cyto-
plasmic vacuoles and large, immature nuclei with an open
chromatin pattern, and CD271/CD146/low cells were gener-
ally smaller than the double-positive cells (supplemental Figure
4A-B). In contrast, CD146 single-positive cells, which did not
contain any CFU-Fs, also had immature nuclei but exhibited a
more basophilic cytoplasm and perinuclear halos, which clearly
distinguished them from CD271-positive CFU-Fs (supple-
mental Figure 4C). We also investigated sorted primary
CD271/CD45 BM-MNCs, which displayed clear morpho-
logic differences compared with the CFU-F–containing
CD271/CD45 cell population (supplemental Figure 2B).
Multicolor FACS analysis of lineage-depleted BM-MNCs
(n  4) was performed to assess the coexpression of signature
mesenchymal and stromal cell-surface marker profiles on
CD271/CD45/CD146/low and CD271/CD45/CD146 cells.
As illustrated in Figure 3C, primary cells from both CFU-F
populations showed coexpression of CD105, CD90, and STRO-1,
as well as PDGFR-beta. The majority of the cells, however, failed
to express SSEA-4 and GD2. However, CD271/CD45 cells
coexpressed integrin  1 (CD49a) (supplemental Figure 4D) and
nestin (supplemental Figure 4E). Endothelial markers such as
Figure 1. All CFU-Fs in human bone marrow are
contained in the CD271/CD45/CD146/low and the
CD271/CD45/CD146 fraction. Freshly isolated hu-
man BM-MNCs were stained with antibodies against
CD271, CD146, and CD45, and analyzed by flow cytom-
etry. Representative contour plots of CD271- and CD146-
expressing human bone marrow cells after forward/side
scatter and 7-AAD gating are shown. (A) CD271 and
CD146 expression in whole viable BM-MNCs. (B) CD271
and CD146 expression after exclusion of CD45
cells. (C) Percentage of CD271/CD45/CD146,
CD271/CD45/CD146, and CD271/CD45/CD146
cells in viable, nondepleted human BM-MNCs (n  9).
Horizontal lines indicate mean values. Error bars show
SEM. (D) Gates for the CD271/CD45/CD146 sorts from
lineage-depleted bone marrow were set according to the
appropriate FMO controls for CD45 (top row left plot). The
top right plot illustrates the CD45-sorting gate, with P10
and P5 indicating the sorting gates for CD45 cells and
CD45 cells, respectively. Red dots indicate all gated
events shown in the CD271/CD146 plot (E) after back-
gating on CD45. Sorting gate definition based on the FMO
controls for CD271 and CD146 are illustrated in the bottom
plots. (E) Sorting gates from a representative bone marrow
sample for CD271/CD146 (P8), CD271/CD146 (P9),
CD271/CD146/low (P7), and CD271/CD146 (P6) after
lineage depletion and CD45 exclusion. As shown in this
analysis, CD146 expression increased gradually with in-
creasing CD271 expression, and therefore it is impossible
to identify a clear-cut CD271/CD146 cell population
within the CD271 cells. We therefore chose instead to
use the term CD271/CD146/low for cells sorted on gate
P7 to indicate this fact. (F) CFU-F frequencies per
100 freshly isolated BM-MNCs of total viable cells sorted
only based on 7-AAD exclusion (viable, n  4), sorted
total CD45 cells (n  4), and the different sorted
CD271/CD146 populations after CD45 exclusion (n  5).
Each dot represents the mean frequency of CFU-Fs from
one bone marrow sample. Horizontal lines indicate mean
values of at least 4-5 independent samples. (G) CFU-F
frequencies per 96-well plate of single-sorted
CD271/CD45/CD146/low and CD271/CD45/CD146
primary cells. Data are shown as mean	 SEM (n 8).
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CD31 and CD34 were only expressed on CD146 single-positive
(ie, non-CFU-F–containing) cells (Figure 3C).
Multiplex single-cell PCR of sorted, uncultured CD271/
CD45/CD146/low cells (Figure 3D) and CD271/CD45/
CD146 cells (Figure 3E) were performed. Tissue-nonspecific
alkaline phosphatase was expressed by virtually all CD271/
CD45/CD146/low and CD271/CD45/CD146 cells. Genes in-
volved in adipogenic differentiation (eg, CEBPA and LPIN1) also
exhibited a similar expression in both CFU-F populations. Further,
both populations expressed genes such as Nanog, Oct-4, and Sox2
(for protein expression, see supplemental Figure 4F). Interestingly,
CD146 expression could also be detected in approximately 40% of
the CD271/CD45/CD146/low cells; however, the band intensity
was weaker compared with CD271/CD45/CD146 cells, thus
matching the flow cytometric profile of a gradually increasing
CD146 expression (Figure 1B and 1E). CD45 expression was
generally not detected.
In vivo differentiation capacity of cultured CD271/CD146/low
and CD271/CD146 cells
CD271/CD45/CD146/low and CD271/CD45/CD146CFU-Fs
were culture expanded in standard MSC medium to obtain
sufficient cell numbers for heterotopic (subcutaneous) and ortho-
topic (intrafemoral) transplantation into immunodeficient mice.
Eight weeks after subcutaneous injection (cultured cells with
HA/TCP carrier particles), bone, adipocytes, fibroblastic tissue,
and capillaries could be detected in both transplants (Figure 4A). In
addition, we detected invading hematopoietic cells in the trans-
plants (Figure 4B).
Orthotopic intrafemoral transplantations into irradiated NOD–
Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice were performed with GFP-labeled
stromal cultures generated from either CD271/CD45/CD146/low or
CD271/CD45/CD146 cells. After 8 weeks, GFP cells could
be detected in the perivascular regions surrounding the endothe-
lium of vessels, as cells lining the surface of cortical and trabecular
bone or surrounding adipocytes, or as reticular cells in the marrow
space (Figure 4C-E). Some of the bone-lining GFP cells were
found to express N-cadherin (Figure 4C). The majority of trans-
planted GFP cells were localized in close proximity (ie, within
20m, corresponding to approximately 2 cells) of the bone surface
and vasculature, respectively (supplemental Table 1). No differ-
ences in the distribution of transplanted CD271/CD45/CD146/low–
derived cells were observed compared with CD271/CD45/
CD146–derived cultures.
Figure 2. Cultured CD271/CD45/CD146/low and
CD271/CD45/CD146 BM-MNCs give rise to stan-
dard mesenchymal stromal cell cultures. Morphology,
differentiation capacity, and FACS profile of cultured
CD271/CD45/CD146/low and CD271/CD45/CD146
cells were compared. (A) Fibroblastic colonies derived
from CD146/low cells and CD146 cells on day 14 shown
with crystal violet staining. Scale bars for the colonies
indicate 400 m; scale bars for the close-ups indicate
50 m. (B) Mean diameter of CD271/CD45/CD146-
and CD271/CD45/CD146/low-initiated colonies (day 14).
Every dot represents one colony (CD146 n 46; CD146/low
n  51) of 2 independent experiments. The lines represent
the mean diameter of the colonies in millimeters. Error
bars represent SEM. (C) In vitro differentiation capacity of
cultures generated from a single CD271/CD45/CD146/low
–sorted cell (top row) and a single CD271/CD45/
CD146–sorted cell (bottom row) from the same bone
marrow sample. Clonal cultures were differentiated
toward the osteoblastic, adipogenic, and chondrogenic
lineage. Osteoblasts were stained with Alizarin Red (left),
and adipocytes were stained with Oil Red O (second from
left). Small inserted photographs show Alizarin Red and
Oil Red O staining on undifferentiated cells. Original mag-
nifications were 40 and 200, respectively. Chondro-
cyte pellets were stained with an anti-aggrecan plus sec-
ondary antibody (third from right). Control sections were
stained with the secondary antibody only (small inserted
photograph). In addition, chondrocyte sections were
stained with toluidine blue (second from right) for pro-
teoglycans and Alcian blue (far right) for metachromasia.
Scale bars indicate 200 m. (D) Representative FACS
profile of single-cell–derived cultured stromal cells. Cells
were measured in the fourth and second passages, when
sufficient amounts were available. Cultures were initiated
with either a CD271/CD45/CD146 (red tinted histo-
grams) or a CD271/CD45/CD146/low (gray tinted his-
tograms) FACS-sorted bone marrow cell. Cultured cells
were stained for typical MSC markers and analyzed by
flow cytometry. Black open histograms represent the cor-
responding isotype controls.
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The principal capacity of transplanted cells to form secondary
colonies was investigated qualitatively in first experiments by
harvesting bone marrow cells from 2 mice 8 weeks after intrafemo-
ral transplantation and plating them for CFU-Fs in standard MSC
culture medium. GFP fibroblastic colonies were detected in the
bone marrow of mice transplanted with CD271/CD45/CD146/low-
or CD271/CD45/CD146–derived cells, thus demonstrating the
principally colony-forming capacity of transplanted BM-MSC–
derived cells. However, these experiments were not designed to
allow for a quantitative analysis.
In situ localization of CD271/CD146/low and CD271/CD146
cells in human bone marrow
To investigate the in situ localization of BM-CFU-Fs, paraffin
sections of normal human bone marrow were stained with antibod-
ies against CD146 and CD271. CD146/CD271 double-positive
cells were observed as perivascular cells surrounding the capillary
endothelium and larger vessels (Figure 5A-B and supplemental
Figure 5B-E). CD271 reticular cells spanned the bone marrow
with long extensions, some of which encircled adipocytes. In
contrast to these CD146/CD271 double-positive cells, we found
that bone-lining cells proximal to the surface of trabecular bone
primarily expressed CD271 alone (Figure 5C and supplemental
Figure 5A). CD146 coexpression by bone-lining cells was rarely
detected. Costaining with CD45 confirmed that no perivascular,
reticular, or bone-lining cells were CD45 (Figure 6A). In the
marrow space, CD271dim-coexpressing hematopoietic CD45 cells
were visible as smaller, round cells (Figure 6A right), and these
cells could easily be distinguished from CD271bright reticular cells
based on their morphology. CD146 was not only expressed by
perivascular cells, but also by -smooth muscle actin (-SMA)–
positive cells within the vascular tunica media (supplemental
Figure 5C), whereas CD271 expression was exclusively confined
to the extraluminal cells in the vascular tunica adventitia (Figure
6B and supplemental Figure 5B). CD271 and CD146 cells in the
tunica adventitia exhibited weak expression of -SMA (Figure 6B
and supplemental Figure 5B-C).
We next investigated the colocalization of CD34 hematopoi-
etic stem/progenitor cells with CFU-Fs in bone marrow sections.
As illustrated in Figure 6, human, round CD34 cells could be
found in proximity to perivascular cells stained with CD271
(Figure 6C). In addition, CD34 cells could be detected in
proximity to trabecular bone-lining CD271 cells (Figure 6D),
although, as expected, only at very low frequencies.
Figure 3. Morphology, surface-marker profile, and
gene expression of primary CD271/CD146/low and
CD271/CD146CFU-Fs. Freshly sorted cells expressing
CD271/CD45/CD146/low (A) and CD271/CD45/
CD146 (B) were allowed to sediment (0 hours) or to
adhere for 24 hours to slides. Photographs were taken on
a differential interference contrast microscope (Axiovert
200M; Zeiss). Scale bars indicate 10 m. (C) Representa-
tive multicolor FACS analysis of primary, lineage-depleted
BM-MNCs after CD45 exclusion. Events are plotted for
CD146 (x-axis) against CD271 (y-axis). Red events in the
plots indicate cells that coexpress the marker listed on top
of the plot: CD105, CD90, STRO-1, PDGFR-, SSEA-4,
GD2, CD31, and CD34. Gray events represent cells that
did not coexpress the listed marker. Each plot represents
an individually stained sample tube from the same bone
marrow sample. The mean percentage of CD271 cells
was of 0.14% 	 0.01% in all plots. (D-E) Single-cell
multiplex PCR of sorted, uncultured CD271/CD45/
CD146/low (D) and CD271/CD45/CD146 (E) cells.
Representative results from one donor are shown. Each
vertical column represents a single cell and each horizon-
tal row represents a certain analyzed gene. Circles indi-
cate expression of the gene, whereas blanks indicate that
no PCR band was detected. In total, sorted cells from
3-4 different donors were analyzed. Numbers indicate the
number (#) and percentage (%) of positive cells per plate
of the donor sample presented in the figure. Data in the
right column represent mean percentages of positive cells
of all analyzed samples. The number of CD271 wells is
set as 100%. For the mean percentages, cells were only
included when they showed a positive band for CD271.
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In vitro CD146 expression is up-regulated during culture and
down-regulated under hypoxic conditions
Sorted CD271/CD146/low and CD271/CD146 cells were
plated on chamber slides and cultured for 6 days at 21% O2. Cells
that initially were CD146/low continued to express CD146 at lower
levels compared with CD146 cells (Figure 7A-B). Conversely,
CD271 expression was comparable (Figure 7A-B). The difference
in CD146 expression could also be observed flow cytometrically
when analyzing lower-passage cultures generated from either
CD146/low or CD146 cells. However, the CD146 expression of
CD271/CD146/low cells progressively increased over time and
attained levels comparable to those observed in cultured CD271/
CD146 cells or cultures generated from unfractionated bone
marrow by the end of the second passage (Figure 7C).
Because the expression levels of CD146 increased in normoxic
culture and was related to the in situ localization of primary
CFU-Fs, we examined the influence of oxygen levels on CD146
expression. Established stromal cultures from unsorted bone mar-
row (third and fourth passage) were cultured with or without
deferoxamine mesylate (DFO) (n  2). FACS analysis on day
7 showed that approximately 25% of the DFO-treated cells had
become negative for CD146, compared with approximately 3.5%
in untreated controls (Figure 7D). No changes in CD90 and CD271
expression were observed (supplemental Figure 6A). This finding
was confirmed in hypoxic chamber experiments (n  2), which
showed that CD146 expression decreased after 2 weeks of culture
in 1% O2 compared with 21% O2 (Figure 7E). This hypoxia-
induced decrease of CD146 expression was reversible when cells
were incubated for an additional 2 weeks at 21% O2 (Figure 7E).
No changes in expression levels could be detected for any of the
remaining surface markers investigated (CD105, CD73, CD90,
HLA class I, and CD271; supplemental Figure 6B).
Discussion
Nonhematopoietic BM-MSCs are capable of generating tissues
such as bone, fat, and cartilage. Furthermore, BM-MSCs also give
rise to the HME, which provides a niche for HSCs in vivo and plays
a pivotal role in regulating, supporting, and maintaining
hematopoiesis.3,19,20
Considerable progress has been made regarding the phenotypic
description of BM-MSCs, and several surface markers for an
effective enrichment of CFU-Fs have been reported. Nonetheless, a
comprehensive characterization of the nonhematopoietic stem cell
system and its different subpopulations is just beginning to emerge.
Furthermore, relatively little is known about BM-MSCs and their
role in the HME.
Recently, Sacchetti et al3 identified a population of CD146
subendothelial human bone marrow cells that contained all assay-
able CFU-Fs and generated bone and HME when transplanted
subcutaneously into immunodeficient mice. CD271 is another
broadly accepted marker for CFU-Fs,6,7 which stains a population
of subendothelial and bone-lining stromal cells in human bone
marrow.21 We show herein by costaining of CD146 and CD271 that
all assayable CFU-Fs were highly and exclusively enriched, not
only in the CD146 fraction of lin/CD271/CD45 stem cells,
but also in the CD146/low fraction, thus complementing the current
knowledge.
Whereas Sacchetti et al used CD146 and CD146 FACS
sorting of MACS CD45-depleted BM-MNCs, we started with a
Figure 4. Ectopic and orthotopic transplantation of cultured cells into immuno-
deficient mice. Multiclonal cultures generated from CD271/CD45/CD146/low and
CD271/CD45/CD146 primary BM-MNCs were transplanted either subcutane-
ously (with HA/TCP particles) or intrafemorally into immunodeficient mice.
(A-B) Representative section of hematoxylin/eosin–stained transplanted cells and
HA/TCP carrier particles 8 weeks after subcutaneous transplantation of
CD271/CD45/CD146–derived MSCs. (A) Bone (b), adipocytes (a), fibroblastic
tissue (ft), and capillaries (*) are indicated. Dark brown areas in the left photograph
indicate HA/TCP carrier particles. Black square in the left photograph is shown as a
magnification (original magnification 10). (B) Invading hematopoietic cells could
be detected in the transplanted cells (black arrow). Original magnification was
10. Scale bar indicates 50 m. (C) GFP cells generated from either
CD271/CD45/CD146/low (top row) or CD271/CD45/CD146 (bottom row)
cells analyzed 8 weeks after intrafemoral transplantation. GFP cells (green)
could be detected as bone-lining cells, some of which expressed N-cadherin
(N-Cad, red) (white arrows, left panels), and in perivascular regions surrounding
the endothelium (CD31, red) (white arrowheads, right panels). (D) Reticular GFP
cells (green) could be detected independently from vessels in the marrow space
(white arrowheads). The photograph shows reticular GFP cells generated from
CD271/CD45/CD146/low cells. (E) Bone marrow section from a control mouse
(injected with Dulbecco PBS only) stained with anti–GFP and CD31 antibody.
Nuclei were stained with TO-PRO3 (blue). Cortical bone (b) is indicated. Scale
bars indicate 25 m. The photographs were taken with a confocal microscope
(DMRE; Leica).
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highly enriched population of lin/CD45/CD271 cells for sort-
ing on CD146 expression, which is the likely reason that the very
rare population of CD146/low CFU-Fs became assayable in our
experiments.
In agreement with previous studies, the majority of CD271
cells coexpressed CD45.22 Therefore, even though CD271—in
contrast to CD146—identified all human BM-CFU-Fs, it is neces-
sary to also exclude CD45 hematopoietic cells from the popula-
tion to reach a high purity of BM-CFU-Fs.
In addition to differences in CD146 expression, both CD271
populations showed comparable BM-MSC properties (morphol-
ogy, surface-marker expression, in vitro and in vivo differentiation
capacities, stroma-supporting capacities, and secondary colony
formation). However, differences in CD146 expression were
Figure 5. In situ localization of CD271 and CD146 bone
marrow cells. Immunofluorescence staining for the in situ
localization of primary BM-MSCs. Paraffin sections of
normal human bone marrow biopsies were stained with
antibodies against CD271 and CD146. (A) Double-positive
cells were detected as reticular cells surrounding the
endothelium of vessels. Photographs in the left and middle
panels illustrate staining against one antigen in double-
stained specimens; these photographs are merged in the
right panel. (B) CD271 reticular cells, shown as green
cells in the left panel and brown cells (black arrowhead) in
the immunohistochemical (IHC) panels, were found as
perivascular cells surrounding the endothelium, shown as
red CD31 cells in the left panel and black arrow in the
middle IHC panel. (C) CD271 bone-lining cells (white
arrowheads in the left panel and black arrowhead in the
IHC photograph) showed no expression of CD146 (green
in the left panel). (B-C) Right IHC panels show a control for
the CD271 staining using an isotype-matched antibody.
IHC photographs were counterstained with hematoxylin.
For confirming IHC expression analysis of CD146 on
bone-lining CD271 cells, see supplemental Figure 5.
Nuclei were stained with TO-PRO3 (blue). Scale bars
indicate 25 m. Asterisk indicates the lumen of a vessel.
Trabecular bone (b) is indicated. Immunofluorescence
photographs were taken with a confocal microscope
(DMRE; Leica); IHC photographs were taken with an
upright microscope (BX51; Olympus).
Figure 6. CD45 and -SMA expression on BM-CFU-Fs
and colocalization of BM-CFU-Fs with CD34 cells.
(A) Human bone marrow paraffin sections were stained
with antibodies against CD271 and CD45. White arrow
indicates a vessel with perivascular CD271/CD45 cells
(left). White arrowheads indicate round, hematopoietic
CD271low/CD45 cells (right). Bone-lining cells in the right
photograph are CD271/CD45. (B) A larger vessel
costained with CD271 and -SMA is shown. White arrow-
heads indicate CD271/-SMAlow perivascular cells.
(C-D) Bone marrow sections were stained against CD34 to
detect hematopoietic stem/progenitor cells and against
CD271 to detect CFU-Fs. (C) Round CD34 cells (green)
were found in proximity to the reticular extensions of
perivascular CD271 cells (red). (D) In rare instances,
round CD34 cells (green) were found neighboring CD271
cells in endosteal regions. White arrowheads indicate
CD34 cells. Nuclei were stained with TO-PRO3 (blue).
Scale bars indicate 25 m. Asterisks indicate the lumen of
a vessel. Trabecular bone (b) is indicated. Photographs
were taken with a confocal microscope (DMRE; Leica).
For the expression of -SMA and perivascular localization
of CD271 cells, see supplemental Figure 5.
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clearly correlated with in situ localization, and therefore enabled us
to identify endosteally localized CD271/CD146/low cells and
perivascular CD271/CD146 cells. These observations agree
with the findings by Sacchetti et al3 on the localization of bone
marrow CD146 adventitial reticular cells and with data by
Cattoretti et al21 reporting that CD271 stromal cells can be found
as either perivascular or bone-lining cells.
As a note of caution, it has not been ultimately proven at
present whether all of the CD271/CD45/CD146/low and
CD271/CD45/CD146 cells that we identified in situ represent
CFU-Fs, because some of the cells could belong to the fraction of
non-colony-forming cells that might still be present even in highly
purified cell populations (here, an even more precise BM-MSCs
phenotype definition would be necessary). From our coexpression
analysis, CD105, CD90, CD49a, PDGFR-, and Stro-1 appear to
be potentially useful as additional CFU-F marker candidates.
However, in contrast to what has been reported previously, we did
not observe expression of SSEA-4 and GD2 on primary BM-
MSCs, which might have been due to differences in staining and
analysis protocols.
In bone marrow sections, both CD271/CD146/low and
CD271/CD146 cells were associated with CD34 hematopoietic
cells, and to our knowledge this is the first report demonstrating the
association of distinct BM-MSC subsets with different potential
HSC niche cell types in the human system. These observations
agree with recently published landmark findings showing that
nestin-positive mesenchymal stem cells form a niche for HSCs in
murine bone marrow.23 In that study, murine nestin/CD45 cells
were identified as a small population of quiescent, perivascular
BM-MNCs, which could differentiate into multiple skeletal lin-
eages, possessed self-renewal capacity, and were required for HSC
homing and maintenance of HSC. Interestingly, the genome-wide
expression profile of these cells was closest to that of human
CD146 BM-MSCs.23 In comparison, the human multipotent
CD271/CD45 BM-MSCs described herein also showed nestin
expression and exhibited hematopoietic stroma characteristics in
Figure 7. In vitro CD146 expression under normoxic
and hypoxic conditions. CD146 expression of
CD271/CD45/CD146/low and CD271/CD45/CD146
cells was monitored over time. Sorted cells from the
CD146/low (A) and the CD146 (B) fractions were plated
on glass chamber slides. Original sorting gates are shown
in red on the left. Cells were incubated at 37°C, 5% CO2,
and 21% O2. On day 6, cells were stained with antibodies
against CD271 (green) and CD146 (red) plus the corre-
sponding secondary antibodies. Small inserted photo-
graphs on the top right show controls stained with second-
ary antibodies only. Scale bars indicate 20 m. (C) CD146
and CD271 expression in cultured cells after the second
passage. Stromal cultures were generated from unsorted
BM-MNCs (top left), bulk-sorted CD271/CD45/CD146/
low cells (top middle), or CD271/CD45/CD146 cells (top
right). FACS plots in the bottom row show CD146 and
CD271 expression of clonal second-passage cultures
from a CD271/CD45/CD146/low–sorted cell (bottom
left) and a CD271/CD45/CD146 sorted cell (bottom
right), respectively. (D) Representative FACS histogram
plot of cells cultured for 1 week with 100M DFO (red open
histogram). Controls were cultured without DFO (gray
tinted histogram). Gray open histogram indicates isotype
control. (E) Representative FACS plots for CD146 expres-
sion of established stromal cells cultured at 21% O2 (gray
tinted histogram, top left) or at 1% O2 (red tinted histogram,
bottom left). Increased expression and reexpression of
CD146, respectively, was observed when both normoxic
and hypoxic stromal cells were passaged and both were
incubated for an additional 2 weeks at 21% O2 (gray and
red tinted histograms in right top and bottom row, respec-
tively). Open histograms represent isotype controls.
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vitro and in vivo. The total population of CD271/CD45 cells in
human BM-MNCs identified in our study was somewhat smaller
(0.03%) than the reported nonhematopoietic nestin-positive popula-
tion (0.08%) in mouse bone marrow; however, CFU-F frequency in
the human CD271/CD45 population was higher (approximately
10-fold) compared with the murine cells.
It has been suggested that different endosteal and perivascular
HSC niche cell types exist, and that different hematopoietic subsets
reside in distinct localizations of the murine bone marrow12-15,24-27;
for example, murine long-term HSCs reside in close proximity to
the endosteal surface of trabecular bone.26 Whether distinct human
CD34 hematopoietic stem- and progenitor-cell populations colo-
calize with different localizations and the different BM-MSC
populations as identified herein is certainly of great interest and
will therefore be addressed in future experiments.
The concept that separate endosteal and perivascular stem cell
niches exist in the bone marrow has been debated. Areas of
trabecular bone are highly vascularized, and therefore endosteally
located HSCs are most likely not only influenced by osteoblastic
signaling, but also by vascular cells.26,27 According to the findings
in murine marrow, we observed a dense vasculature network in the
human bone marrow biopsies studied, with vessels also located
near the surface of trabecular bone. Nevertheless, it has been
clearly demonstrated that an oxygen gradient exists in the bone
marrow and that HSCs are localized at the lowest end of the
gradient in hypoxic niches28-32 such as the bone surface area.28 We
also observed that in vitro CD146 expression was dependent on
oxygen levels and that in situ CD146 expression near the bone
surface was absent or very weak. These observations might partly
be explained by lower oxygen levels at the endosteum; however,
additional mechanisms such as calcium-induced CD146 shedding
might be operative as well,33 because calcium levels are high near
activated osteoclasts at the endosteal surface.34
In summary, we have defined the phenotype of human primary
nonhematopoietic BM-MSCs based on the expression of CD271,
CD45, and CD146. We demonstrate that CD146 expression in
lineage-negative, NGFR-positive, common leukocyte antigen–
negative stroma stem cells is correlated with in situ localization,
and that different BM-MSC subpopulations colocalize with differ-
ent putative HSC niche cell types. This is an important finding that
is likely to be the first step toward a better characterization of the
human HME, hopefully leading to a better understanding of niche
anatomy and function in normal and diseased marrow.
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